Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ALPMY NASDAQ:RPRX OTCMKTS:SSDOY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPMYAstellas Pharma$14.67+1.5%$15.57$8.97▼$17.35$26.15B0.08152,208 shs169,802 shsRPRXRoyalty Pharma$50.79+1.2%$47.62$32.15▼$51.65$28.96B0.43.26 million shs3.76 million shsSSDOYShiseido$21.80+3.4%$20.03$13.60▼$22.32$8.42B0.2820,913 shs13,557 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPMYAstellas Pharma+0.63%+1.05%-11.67%-8.20%+45.52%RPRXRoyalty Pharma-1.11%+0.22%+7.10%+12.43%+53.26%SSDOYShiseido-0.33%+2.83%-2.68%+17.90%+29.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPMYAstellas Pharma$14.67+1.5%$15.57$8.97▼$17.35$26.15B0.08152,208 shs169,802 shsRPRXRoyalty Pharma$50.79+1.2%$47.62$32.15▼$51.65$28.96B0.43.26 million shs3.76 million shsSSDOYShiseido$21.80+3.4%$20.03$13.60▼$22.32$8.42B0.2820,913 shs13,557 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPMYAstellas Pharma+0.63%+1.05%-11.67%-8.20%+45.52%RPRXRoyalty Pharma-1.11%+0.22%+7.10%+12.43%+53.26%SSDOYShiseido-0.33%+2.83%-2.68%+17.90%+29.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPMYAstellas Pharma 2.80Moderate BuyN/AN/ARPRXRoyalty Pharma 3.00Buy$53.715.76% UpsideSSDOYShiseido 2.75Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ALPMY, SSDOY, and RPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RPRXRoyalty Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $66.005/7/2026RPRXRoyalty Pharma JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $58.005/1/2026RPRXRoyalty Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)4/24/2026ALPMYAstellas Pharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/21/2026RPRXRoyalty Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$51.00 ➝ $57.004/10/2026RPRXRoyalty Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$61.00 ➝ $63.003/24/2026ALPMYAstellas Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/27/2026RPRXRoyalty Pharma TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy2/24/2026SSDOYShiseido Smbc Nikko Sec.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold2/16/2026ALPMYAstellas Pharma Smbc Nikko Sec.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold2/12/2026RPRXRoyalty Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPMYAstellas Pharma$14.21B1.87$1.83 per share8.03$5.52 per share2.66RPRXRoyalty Pharma$2.38B12.32$4.83 per share10.51$17.23 per share2.95SSDOYShiseido$6.49B1.34$1.36 per share16.01$10.42 per share2.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPMYAstellas Pharma$1.94B$1.0713.6611.03N/A13.66%24.19%11.30%N/ARPRXRoyalty Pharma$770.95M$1.4734.559.291.3833.88%29.25%14.71%N/ASSDOYShiseido-$272.55M-$0.70N/A23.960.90-4.27%0.97%0.48%5/11/2026 (Estimated)Latest ALPMY, SSDOY, and RPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026N/ASSDOYShiseido$0.0916N/AN/AN/A$1.48 billionN/A5/6/2026Q1 2026RPRXRoyalty Pharma$1.22$1.30+$0.08$0.67$881.69 million$631.00 million4/27/2026Q4 2026ALPMYAstellas Pharma$0.1941$0.33+$0.1359$0.15$3.28 billion$3.38 billion2/11/2026Q4 2025RPRXRoyalty Pharma$1.33$1.46+$0.13$0.50$839.97 million$621.99 million2/10/2026Q4 2025SSDOYShiseido-$0.0956$0.0531+$0.1486$0.05$1.77 billion$1.77 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALPMYAstellas Pharma$0.342.32%N/A31.78%N/ARPRXRoyalty Pharma$0.941.85%+24.01%63.95%5 YearsSSDOYShiseido$0.160.73%N/AN/A N/ALatest ALPMY, SSDOY, and RPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/17/2026RPRXRoyalty Pharmaquarterly$0.23501.88%5/15/20265/15/20266/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPMYAstellas Pharma0.231.090.84RPRXRoyalty Pharma0.862.662.40SSDOYShiseido0.441.370.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPMYAstellas PharmaN/ARPRXRoyalty Pharma54.35%SSDOYShiseido0.02%Insider OwnershipCompanyInsider OwnershipALPMYAstellas PharmaN/ARPRXRoyalty Pharma18.84%SSDOYShiseidoN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPMYAstellas Pharma14,7541.81 billionN/ANot OptionableRPRXRoyalty Pharma80576.86 million468.18 millionOptionableSSDOYShiseido27,908399.53 millionN/ANot OptionableALPMY, SSDOY, and RPRX HeadlinesRecent News About These CompaniesShiseido (SSDOY) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comShiseido Co. Ltd. ADRMay 2, 2026 | marketwatch.comShiseido Co. (OTCMKTS:SSDOY) Short Interest UpdateApril 26, 2026 | marketbeat.comShiseido (OTCMKTS:SSDOY) Shares Gap Down - What's Next?April 16, 2026 | marketbeat.comShiseido (OTCMKTS:SSDOY) Trading Down 5.7% - Here's What HappenedApril 13, 2026 | marketbeat.comShiseido Co. (OTCMKTS:SSDOY) Short Interest Down 42.1% in MarchApril 13, 2026 | marketbeat.comShiseido (OTCMKTS:SSDOY) Shares Gap Down - Here's WhyApril 10, 2026 | marketbeat.comShiseido (OTCMKTS:SSDOY) Reaches New 52-Week High - Here's What HappenedApril 8, 2026 | marketbeat.comShiseido Co Ltd ADR SSDOYMarch 12, 2026 | morningstar.comMShiseido Surges 15% After 61.4% Profit Jump, Forecast BeatsFebruary 13, 2026 | finance.yahoo.comGoldman Sachs Keeps Their Buy Rating on Shiseido Company,Limited (4911)January 17, 2026 | theglobeandmail.comShiseido upgraded to buy from neutral at Goldman SachsDecember 10, 2025 | msn.comShiseido Company, Limited (SSDOY) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comShiseido: There's Motivation To Improve Returns With New Performance Indicators (Rating Upgrade)July 22, 2025 | seekingalpha.comShiseido Americas to Slash Workforce as Sales PlummetJuly 18, 2025 | globalcosmeticsnews.comGLayoffs Hit Shiseido AmericasJuly 18, 2025 | msn.comShiseido Americas to make ‘significant’ job cutsJuly 18, 2025 | cosmeticsbusiness.comCShiseido Company Stock Price History - Investing.comJuly 4, 2025 | investing.comShiseido giving away £90 anti-ageing serum that shrinks 'fine lines' in daysJuly 1, 2025 | mirror.co.ukMShiseido taps AI, online channels and slow ageing trend to stay relevantJune 20, 2025 | straitstimes.comSShiseido bottles cosmetics with refillable LiquiForm container to cut plasticsJune 19, 2025 | packagingeurope.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALPMY, SSDOY, and RPRX Company DescriptionsAstellas Pharma OTCMKTS:ALPMY$14.67 +0.22 (+1.52%) As of 03:55 PM EasternAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Royalty Pharma NASDAQ:RPRX$50.79 +0.59 (+1.18%) Closing price 04:00 PM EasternExtended Trading$50.52 -0.27 (-0.52%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Shiseido OTCMKTS:SSDOY$21.80 +0.72 (+3.42%) As of 03:57 PM EasternShiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
